Publications by authors named "David Recker"

Claim this Profile
A
A Randomized Parallel-group Study of Digital Gut-directed Hypnotherapy vs Muscle Relaxation for Irritable Bowel Syndrome.
Sameer K Berry, Rani Berry, David Recker, Jeffrey Botbyl, Lucy Pun

Clin Gastroenterol Hepatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-Five Years' Experience and Beyond with Cultured Epidermal Autografts for Coverage of Large Burn Wounds in Adult and Pediatric Patients, 1989-2015.
William L Hickerson, Ann E Remmers, David P Recker

J Burn Care Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial.
Mats Brittberg, David Recker, John Ilgenfritz, Daniel B F Saris,

Am J Sports Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ixCELL-DCM Trial: Rationale and Design.
Timothy D Henry, Gary L Schaer, Anthony DeMaria, David Recker, Ann E Remmers

Cell Transplant· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.
Amit N Patel, Timothy D Henry, Arshed A Quyyumi, Gary L Schaer, R David Anderson, David Recker

Lancet· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy.
Timothy D Henry, Jay H Traverse, Baron L Hammon, Cara A East, Brian Bruckner, David Recker

Circ Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imperative to care.
David R Recker, Arthur I Schwartz

J Mass Dent Soc· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study.
Leanne M Redman, Lilian de Jonge, Xiaobing Fang, Betsy Gamlin, David Recker

J Clin Endocrinol Metab· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics.
Trevor T Hansel, Sergei A Kharitonov, Louise E Donnelly, Edward M Erin, Mark G Currie, David P Recker

FASEB J· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
Philip T Leese, David P Recker, Jeffrey D Kent

J Clin Pharmacol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty.
Lowell W Reynolds, Robert K Hoo, Robert J Brill, Janine North, David P Recker

J Pain Symptom Manage· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
David H Sikes, Naurang M Agrawal, William W Zhao, Jeffrey D Kent, David P Recker

Eur J Gastroenterol Hepatol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain.
Paul J Desjardins, Vincent S Shu, David P Recker, Kenneth M Verburg, Clifford J Woolf

Anesthesiology· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
Stephen E Daniels, Sheela Talwalker, Sarah Torri, Michael C Snabes, David P Recker

Obstet Gynecol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valdecoxib does not impair platelet function.
Philip T Leese, Sheela Talwalker, Jeffrey D Kent, David P Recker

Am J Emerg Med· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery.
James Fricke, John Varkalis, Sam Zwillich, Rebecca Adler, Eliot Forester, David P Recker

Am J Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
Alan Kivitz, Glenn Eisen, William W Zhao, Terry Bevirt, David P Recker

J Fam Pract· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery.
Stephen E Daniels, Paul J Desjardins, Sheela Talwalker, David P Recker, Kenneth M Verburg

J Am Dent Assoc· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen.
W Makarowski, William W Zhao, Terry Bevirt, David P Recker

Osteoarthritis Cartilage· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty.
Frederic Camu, Tessa Beecher, David P Recker, Kenneth M Verburg

Am J Ther· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis